EcoDrugPlus

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSCSAG00000011238
Gene Symbol: CYP19A1
3 Cross references
319 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 26 Subfamily A Member 1

Ensembl ID : ENSCSAG00000006513
Gene Symbol: CYP26A1
3 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 3 Subfamily A Member 43

Ensembl ID : ENSCSAG00000017826
Gene Symbol: CYP3A43
3 Cross references
652 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 3 Subfamily A Member 5

Ensembl ID : ENSCSAG00000017809
Gene Symbol: CYP3A5
5 Cross references
643 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 3 Subfamily A Member 7

Ensembl ID : ENSCSAG00000017821
Gene Symbol: CYP3A7
3 Cross references
644 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cytochrome P450 Family 46 Subfamily A Member 1

Ensembl ID : ENSCSAG00000010408
Gene Symbol: CYP46A1
5 Cross references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Diacylglycerol O-Acyltransferase 1

Ensembl ID : ENSCSAG00000008609
Gene Symbol: DGAT1
5 Cross references
262 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dihydrofolate Reductase

Ensembl ID : ENSCSAG00000015136
Gene Symbol: DHFR
3 Cross references
316 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSCSAG00000004239
Gene Symbol: DHODH
5 Cross references
173 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSCSAG00000001495
Gene Symbol: DPYD
5 Cross references
223 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dipeptidyl Peptidase 4

Ensembl ID : ENSCSAG00000015640
Gene Symbol: DPP4
5 Cross references
286 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSCSAG00000002747
Gene Symbol: DDR2
3 Cross references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).